BSH/UKMF

These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.

These updated guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the diagnosis and management of myeloma patients. They should be read in conjunction with the BCSH Guidelines on the supportive care of myeloma patients.

These guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the supportive care of myeloma patients and should be read in conjunction with the BCSH Guidelines for the diagnosis and management of myeloma.

Consolidation or maintenance treatment are possible strategies that can be utilised to improve patient outcomes but their optimal use have yet to be defined. In this paper, the UK Myeloma Forum reviews the current position of maintenance and consolidation treatment for myeloma patients in the UK.

The benefits of bendamustine are increasingly being recognised in the relapsed setting but its optimal use has yet to be defined. Based on a review of current data, the UK Myeloma Forum has produced a position statement providing recommendations for the use of bendamustine as a treatment for myeloma patients in the UK.

This paper provides updated guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas and incorporates further available information on diagnosis, prognosis and management and a new section on the management of multiple solitary plasmacytomas.

These guidelines, written by the UK Myeloma Forum in conjunction with the Nordic Myeloma Study Group provide guidance for the effective clinical investigation of patients with newly detected paraprotein and the practical management of patients with monoclonal gammopathy of undetermined significance (MGUS).

This paper, written by a joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology and the British Society for Bone Marrow Transplantation, reviews the available literature and made recommendations for the supportive care and management of organ-specific complications of chronic graft-versus-host disease (cGvHD).

This guideline, produced by a joint working group established by the Haemato-Oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Bone Marrow Transplantation (BSBMT) reviews the available literature and makes recommendations for the diagnosis and management of chronic graft-versus-host disease (GvHD).